HEDS is part of the School of Health and Related Research (ScHARR) at the University of Sheffield. We undertake research, teaching, training and consultancy on all aspects of health related decision science, with a particular emphasis on health economics, HTA and evidence synthesis.

Monday, 16 October 2017

September’s CEAs.....

Our quick search for CEA’s published in September uncovered 40 articles.   In the right-hand column of this blog is a CEA Archive, which includes our CEA search results by month.  Below are those in our areas of interest.
  • Gray E, Donten A, Karssemeijer N, van Gils C, Evans DG, Astley S, et al. Evaluation of a Stratified National Breast Screening Program in the United Kingdom: An Early Model-Based Cost-Effectiveness Analysis. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2017;20(8):1100-9.
  • Jendle J, Smith-Palmer J, Delbaere A, de Portu S, Papo N, Valentine W, et al. Cost-Effectiveness Analysis of Sensor-Augmented Insulin Pump Therapy with Automated Insulin Suspension Versus Standard Insulin Pump Therapy in Patients with Type 1 Diabetes in Sweden. Diabetes therapy : research, treatment and education of diabetes and related disorders. 2017.
  • Jowett S, Barton P, Roalfe A, Fletcher K, Hobbs FDR, McManus RJ, et al. Cost-effectiveness analysis of use of a polypill versus usual care or best practice for primary prevention in people at high risk of cardiovascular disease. PloS one. 2017;12(9):e0182625.
  • Pearson-Stuttard J, Hooton W, Critchley J, Capewell S, Collins M, Mason H, et al. Cost-effectiveness analysis of eliminating industrial and all trans fats in England and Wales: modelling study. Journal of public health (Oxford, England). 2017;39(3):574-82.

Friday, 13 October 2017

HEDS Discussion Papers available on Open Access database

HEDS produces its own series of discussion papers which started way back in 2001 with a paper by Professor John Brazier, who is now the Dean of ScHARR. The complete series of 137 papers can now be accessed on our own institutional White Rose open access repository. The collection can be viewed and downloaded by going to here

Image of the front cover of the first HEDS Discussion Paper
The first HEDS Discussion Paper 

The series is intended to promote discussion papers in progress. The Views expressed are those of the authors, and therefore should not be quoted without their permission. However, comments are welcome and we ask that they be sent direct to the corresponding author.

Wednesday, 11 October 2017

HEDS international visit to Centre for Infectious Disease Epidemiology and Research

Image of Dr Bell Gorrod with Dr Michael Schomaker, and Professor Mary-Ann Davies
Dr Bell Gorrod with Dr Michael Schomaker,
and Professor Mary-Ann Davies
Dr Helen Bell Gorrod recently visited the Centre for Infectious Disease Epidemiology and Research (CIDER) at the University of Cape Town (UCT). Helen successfully obtained funding for the visit from the Worldwide University Network (WUN) Research Mobility Programme (RMP). 

During the month long visit, Helen worked on a collaborative research project with Dr Michael Schomaker, Professor Mary-Ann Davies and others at UCT. 

The project aimed to assess the impact of delays in viral load testing and treatment switching from first-line to second-line ART treatment regime for HIV patients on hospitalisation and mortality outcomes using causal inference statistical methods. 

Tuesday, 10 October 2017

HEDS in the media - July to September 2017

A lot of the research that ScHARR and HEDS conducts gains media and online attention. As with the last few quarterly periods we have taken a quick look at some the attention using Altmetrics to see what has been said about our work and how far and wide it has reached on social media channels.

HEDS work is regularly mentioned across the media, blogs, social media as well as getting cited in policy documents and Wikipedia entries. On the blog we often take a regular look as to the latest coverage our research receives using Altmetric data that scrapes the web for mentions of our work using DOIs and other unique identifiers. Since the end of June our work and collaborations have received an awful lot of attention. In total we received 3824 total mentions, of which 3,494 were Tweets, whilst we were featured or had our work linked to 101 news articles, 53 blogs and 105 Facebook Shares. HEDS work was also cited 36 times in policy documents (including translated and other versions) and appeared as six Wikipedia citations.

Image of data showing Tweets per country
Tweets by country

Work by Professor Allan Brennan and Colin Angus on impact of local alcohol licensing policies was cited in a The Conversation article and subsequent Yahoo News! story on binge drinkers back in August. Previous alcohol research by Brennan and Angus was also cited in a number of stories in the U.S. starting from Bloomberg and re-run in True Viral News, Arkansas Online, The Journal Gazette, The Keene Sentinel, The Bakersfield Californian and The Salt Lake Tribune. Our work was cited in news across 101 stories, in 69 unique outlets in 13 countries.

Image of graph showing news coverage per country
News coverage by country
Looking at the policy documents, Professor Ben Van Hout’s work before he joined ScHARR is featured in a couple of publications. A paper published back in 1994 for Health Economics is cited in a NICE CDF Rapid Reconsideration on Cetuximab for the treatment of metastatic and/or recurrent squamous cell carcinoma of the head and neck (review of TA172)
Work involving Dr Andrew Booth from a paper published in PLoS Medicine is also cited in the NICE Clinical Guideline; Faltering Growth - recognition and management.


Monday, 9 October 2017

Latest Publications from HEDS in September

Our regular monthly trawl for new publications from HEDS in collaboration with colleagues in ScHARR and further afield never fails to discover fresh research. Many of these are currently in press and you can find much of our work in its open access form via our institutional repository. Tuck in here. 

Image of Journal of Health Economics cover
© Elsevier                              
Brazier J, Rowen DL, Karimi M, Peasgood T, Tsuchiya A, Ratcliffe J. Experience-based utility and own health state valuation for a health state classification system: why do it and how to do it. European Journal of Health Economics

Chambers D, Preston L, Topakas A, de Saille S, Salway S, Booth A, Dawson J, Wilsdon J. Review of diversity and inclusion literature and an evaluation of methodologies and  metrics relating to health research. Available at: https://wellcome.ac.uk/sites/default/files/review-of-diversity-and-inclusion-literature.pdf

Poku EN, Aber A, Phillips P, Essat M, Woods H, Palfreyman S, Kaltenthaler E, Jones G, Michaels J. Systematic review assessing the measurement properties of patient-reported outcomes for venous leg ulcers. British Journal of Surgery

Image of Journal of Epidemiology and Community Health Journal
© BMJ Journals
Sadler S, Tosh J, Pennington R, Rawdin A, Squires H, Romero C, Fischer A, Chilcott J. A cost-effectiveness analysis of condom distribution programmes for the prevention of sexually transmitted infections in England. Journal of Epidemiology and Community Health (2017) 71:897–904. doi:10.1136/jech-2017-209020

Chambers D, Preston L, Salway S, De Saille S, Topakas A, Booth A, Dawson J, Wilsdon JR. The Diversity Dividend: does a more diverse and inclusive research community produce better biomedical and health research? Sheffield: TUOS/Wellcome Trust (2017). Available at: https://wellcome.ac.uk/sites/default/files/the-diversity-dividend-briefing.pdf

Dixon S. Determining the relative cost effectiveness of the fluocinolone acetonide intravitreal implant. Current Medical Research and Opinion (2017) 33:1–2. doi:10.1080/03007995.2017.1366624

Image of PharmacoEconomics Journal
© Adis
Brazier JE, Muston D, Konwea H, Power GS, Barzey V, Lloyd A, Sowade O, Vitti B, Gerlinger C, Roberts. Evaluating the Relationship Between Visual Acuity and Utilities in Patients With Diabetic Macular Edema Enrolled in Intravitreal Aflibercept Studies. Investigative Ophthalmology & Visual Science (2017) 58:4818–4825. doi:10.1167/iovs.17-21945

Bermejo I, Stevenson M, Cooper K, Harnan S, Hamilton J, Clowes M, Carroll C, Harrison T, Saha S. Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics (2017) doi:10.1007/s40273-017-0571-8

Bermejo I, Tappenden P, Youn J-H. Response to “Comment on ‘Replicating Health Economic Models: Firm Foundations or a House of Cards?’”. Pharmacoeconomics (2017) doi:10.1007/s40273-017-0574-5

Friday, 6 October 2017

Two Health Economics and Decision Modelling training posts in HEDS

We are currently looking for two Grade 6 Research Assistants.  The posts involve part time working and part time study on the HEDM MSc.  The posts are ideal for researchers with limited experience, or wishing to convert their stats/maths skills into decision modelling and related topics.

If you want to know more, look here.  The closing date is the 8th October.

Thursday, 5 October 2017

NICE budget impact test cleared by High Court

The test, which was introduced this year, states that “if the budget impact exceeds £20million, in any of the first 3 years, NHS England may engage in commercial discussions with the company. These discussions are designed to mitigate the impact that funding the technology would have on the rest of the NHS.”

The ABPI took a legal challenge to the High Court and lost.  NHS England were like a dog with two tails, saying:
“In this ruling the High Court has rejected ABPI’s flawed legal manoeuvres which the judge said would ‘produce an absurd result’. Rather than attempting to further frustrate NICE and the NHS’ work to ensure patients and taxpayers get maximum value out of the £15 billion being spent on drugs, it now makes sense to work together towards that shared goal.”

NHS England chooses which medicine should not be prescribed in primary care

Well, sort of.  It has opened a consultation on “Items which should not be routinely prescribed in primary care: A Consultation on guidance for CCGs”.  It closes on 21st Oct 2017.

Further details can be found here.

Wednesday, 4 October 2017

Health Services & Delivery Research Programme Evidence Synthesis Centre

Image of ScHARR
ScHARR - Regent Court
Earlier in 2017 HEDS, in collaboration with ScHARR’s Public Health Section, successfully won a £500,000 three-year competitive tender from the National Institute for Health Research to renew its Health Services & Delivery Research Programme Evidence Synthesis Centre (ESC). 

The Sheffield ESC is one of three, formerly two, centres (the others being in Exeter and York) that offer a rapid response reviews service on Programme priorities to inform policy and research. Typically, a small team, comprised of reviewers and information specialists, works within a rapid review timetable proposing an appropriate methodology and review type for each question. Currently, our team is conducting a mapping and realist review looking at implementation of successful interventions to reduce preventable hospital admissions.

HEDS-based ESC core staff include Anna Cantrell and Dr Louise Preston with Dr Andrew Booth, who is co-Director with Professor Elizabeth Goyder of the Public Health Section. Meanwhile the team’s report distilling methodological and organisational lessons learned from the first three years of the Sheffield and York ESCs is now available:  
Chambers, D., Booth, A., Rodgers, M. et al. (2017) NIHR HS&DR evidence synthesis centres: achievements and learning from the first three year programme, 2014–2017. Report. NIHR Journals Library, Southampton. http://eprints.whiterose.ac.uk/120637/3/HS%26DR%2013.05.12%20%2813.182.12%29%20Web%20Report-1-White%20Rose.pdf

Meanwhile Andrew Booth, as senior review methodologist, joined a School of Nursing-led team to successfully secure a five year contract to form a Royal College of Nursing/University of Sheffield strategic alliance for research.   

Tuesday, 3 October 2017

Cochrane Collaboration Issue 9, 2017…

….is complete.  The website lists protocols and methodology papers as well, but we’ll just flag up the notable reviews; these being……
  • Direct‐acting antivirals for chronic hepatitis C
  • Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
  • Vitamin A supplements for reducing mother‐to‐child HIV transmission
  • Implementation strategies for health systems in low‐income countries: an overview of systematic reviews
  • Financial arrangements for health systems in low‐income countries: an overview of systematic reviews